Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Mantle cell lymphoma (MCL) is a B-cell malignancy with heterogeneous clinical behavior.
• Advances in risk stratification distinguish conventional MCL (cMCL) from non-nodal MCL (nnMCL) subtypes with unique features.

Purpose of the Study:

• To review current prognostic factors and emerging strategies for Mantle Cell Lymphoma.
• To highlight the role of TP53 disruption and minimal residual disease (MRD) monitoring in MCL management.

Main Methods:

• Review of prognostic tools including MIPI/MIPI-c, Ki-67, and TP53 mutation/deletion status.
• Discussion of emerging genomic alterations (e.g., 17p deletion, CDKN2A loss) as prognostic factors.
• Exploration of minimal residual disease (MRD) monitoring as a dynamic prognostic tool.

Main Results:

• TP53 disruption is identified as a major adverse factor associated with poor outcomes in MCL.
• New genomic alterations are emerging as significant prognostic indicators.
• Minimal residual disease (MRD) monitoring shows potential for dynamic risk assessment and treatment adaptation.

Conclusions:

• Effective management of high-risk MCL remains challenging despite new therapies.
• Integrating molecular predictors, clinical data, and MRD monitoring is crucial for personalized MCL treatment strategies.
• Personalized therapeutic strategies incorporating MRD monitoring could form the future algorithm for MCL management.